Hemab Therapeutics is a clinical-stage biotech developing subcutaneous prophylactic therapies for rare bleeding disorders. The company's two clinical assets address conditions where no approved prophylactic options currently exist. Sutacimig (HMB-001) is a bispecific antibody in development for Glanzmann thrombasthenia (a platelet dysfunction disorder) and Factor VII deficiency; it works by directing circulating Factor VII to activated platelets at bleeding sites to concentrate clotting activity locally. HMB-002 is a monovalent antibody for Von Willebrand Disease, the most common inherited bleeding disorder; it extends the half-life of von Willebrand factor, raising circulating levels of both VWF and Factor VIII. Both assets are designed for subcutaneous dosing, targeting a prophylactic approach rather than the reactive, on-demand treatments patients currently rely on. Hemab retains global rights to both assets and plans to commercialize directly in the U.S., EU, Japan, and select other markets, arguing that patients are concentrated in specialized treatment centers, enabling a small commercial team to reach relevant prescribers efficiently. The company is pre-revenue and funds operations through equity, having raised approximately $346M since inception. If approved, products would be priced as orphan drugs. Sutacimig carries financial obligations to Novo Nordisk (low single-digit royalties on net sales) and Genmab (low-teens net profit share pre-commercialization). Neither product has entered a pivotal trial, and sutacimig has an open safety question around thromboembolic events observed in clinical testing.